Our Research and Development area has worked for more than 10 years consolidating a pharmaceutical platform that has allowed the generation of a portfolio of propietary products that cover different unresolved oral pathologies.
Through our innovative pharmaceutical platform, we create unconventional and easy-to-use products aimed to control various oral pathologies, providing relief to patients.
Well-being for Everyone
At Ingalfarma we strive every day to provide relief to our patients, support health professionals, maintain good relationships with our clients and providers, make sure our collaborators have a good quality of life and be a contribution our society.
Ingalfarma is a specialty pharmaceutical company, focused on oral pathologies. Our Research and Development area has worked for more than 10 years consolidating a pharmaceutical platform that has allowed the generation of a portfolio of propietary products.
Our product portfolio covers a wide range of oral manifestations such as oral mucositis, aphthous stomatitis and other oral injuries due to autoimmune diseases or mechanical damage, cold sores, periodontitis, among others.
With over 40 years of experience, Dr. Galván has developed many initiatives in the public and private sectors. Scientist and serial entrepreneur, he is responsible for the development pipeline, inventor and author of a large number of international patents.
Since 2009, David serves as the Director of Graduate Studies of the Faculty of Dentistry and part of the academic staff of Department of Oral and Maxillofacial Surgery at the Los Andes University, Chile. Dr. Rosenberg is an established lecturer and well-published researcher in International journals. He is an active member of the European Association of Osseointegration and the Academy of Osseointegration. Today, he is leading the clinical development area and posseses international patents.
In 1981, together with W. Rutter and E. Penhoet, founded Chiron Corporation, which a decade later was the second-largest biotechnology company in the world. As Vice President of R&D, Valenzuela was responsible for the development of biotech products with a market value of nearly 8 billion dollars and inventor in more than 50 patents in Chile and abroad. Dr. Valenzuela founded GrupoBios S.A., the first biotech company in Chile and in 1997 he cofounded Fundación Ciencia & Vida.
He is professor of Universidad Católica and Universidad Andrés Bello and is a member of the Chilean Academy of Sciences. In 2002, he was given the Chilean National Award for Applied Sciences. Recently he received the Life Time Achievement Award from the BayBio Association of California.
As a seasoned executive, Mr. Hernández has invested in and mentored numerous Chilean, US and British biotechnology companies. He also lectures on Science and Business at the Biotechnology Ph.D Program of the Universidad Nacional Andrés Bello. He holds a Masters in BioScience Enterprise from the University of Cambridge, England, and an undergraduate degree in Molecular Biotechnology Engineering from the Universidad de Chile.
We care about our environment
The pharmaceutical plant has state-of-the-art technology, mainly of German and Italian origin, in addition to rigorous quality controls and permanent preventive maintenance plans, allowing high standards of operation and productivity.
1. INGALFARMA CLOSES SUCCESSFUL FINANCING ROUND
Link » kamagra pillen kopen
3. DENTOXOL® ENTERS GES PROGRAMME
Ingalfarma announces that its product Dentoxol® has been incorporated into the GES programme of one of the most important health insurance companies in the country,